Lembaz is now
FDA approved1,2
Lembaz is indicated to reduce the risk of mortality in adult and pediatric patients, who weigh 7 kg or greater, with Niemann-Pick disease type C (NPC) with neurological manifestations that started at less than 6 years of age.1,2
Woodrow, a real patient receiving Lembaz since 20 months old, diagnosed with I-NPC at 3 months old. Individual results may vary.
I-NPC=infantile-onset NPC.
Peer support for patients
The Caregiver Ambassador Program connects your patients’ caregivers with others who have navigated I-NPC and treatment with Lembaz.
Accessing Lembaz starts here
The following forms and guides are intended for healthcare professionals and office staff to help patients access Lembaz.
Patient Enrollment Form
Completed by healthcare professionals to order Lembaz and enroll patients in LembazTM Family Support
Letter of Medical Necessity Template
Template for healthcare professionals to support coverage requests by documenting a patient’s medical need for Lembaz
Prior Authorization Checklist
A checklist for healthcare professionals to help prepare and submit prior authorization documentation for Lembaz
Billing and Coding Guide
Billing and coding information for healthcare professionals to help support patient access to Lembaz
Dosing and Administration Guide
Information about Lembaz dosing, administration, and monitoring
Emmy, a real patient receiving Lembaz since 2.5 years old, diagnosed with I-NPC at 8 months old, and her mom. Individual results may vary.
Stay connected
Sign up to receive information about Lembaz and how you can best support your patients living with I-NPC.
Have questions about Lembaz?
Connect with a Lembaz Key Account Manager (KAM) for product, treatment, or access support.